Search

Haemonetics Corp

Cerrado

SectorSanidad

77.01 -1.17

Resumen

Variación precio

24h

Actual

Mínimo

75.84

Máximo

78.29

Métricas clave

By Trading Economics

Ingresos

-65M

-20M

Ventas

7.4M

346M

P/B

Media del Sector

38.132

62.58

BPA

1.29

Margen de beneficios

-5.817

Empleados

3,009

EBITDA

-91M

4.3M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+0.82% upside

Dividendos

By Acuity

Próximas Ganancias

6 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

982M

3.6B

Apertura anterior

78.18

Cierre anterior

77.01

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

145 / 340 Clasificación en Healthcare

Haemonetics Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

20 jul 2026, 18:46 UTC

Haemonetics Corp shares are higher today, continuing gains since Friday's close. The stock reached a session high earlier, though it has pulled back.

Comparación entre iguales

Cambio de precio

Haemonetics Corp previsión

Precio Objetivo

By TipRanks

0.82% repunte

Estimación a 12 Meses

Media 78.71 USD  0.82%

Máximo 90 USD

Mínimo 62 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Haemonetics Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

9 ratings

6

Comprar

3

Mantener

0

Vender

Sentimiento

By Acuity

145 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Haemonetics Corp

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.